Resmed (RMD) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Resmed (RMD) over the last 16 years, with Q4 2025 value amounting to $8.5 billion.
- Resmed's Liabilities and Shareholders Equity rose 1907.26% to $8.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.6 billion, marking a year-over-year increase of 1605.03%. This contributed to the annual value of $8.2 billion for FY2025, which is 1894.53% up from last year.
- According to the latest figures from Q4 2025, Resmed's Liabilities and Shareholders Equity is $8.5 billion, which was up 1907.26% from $8.3 billion recorded in Q3 2025.
- In the past 5 years, Resmed's Liabilities and Shareholders Equity registered a high of $8.5 billion during Q4 2025, and its lowest value of $4.6 billion during Q1 2021.
- Over the past 5 years, Resmed's median Liabilities and Shareholders Equity value was $6.7 billion (recorded in 2023), while the average stood at $6.4 billion.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 4100.25% in 2022, then surged by 149.96% in 2024.
- Resmed's Liabilities and Shareholders Equity (Quarter) stood at $4.7 billion in 2021, then skyrocketed by 41.0% to $6.7 billion in 2022, then increased by 3.43% to $6.9 billion in 2023, then grew by 3.42% to $7.1 billion in 2024, then grew by 19.07% to $8.5 billion in 2025.
- Its last three reported values are $8.5 billion in Q4 2025, $8.3 billion for Q3 2025, and $8.2 billion during Q2 2025.